Serum inhibin A and activin A are elevated prior to the onset of pre-eclampsia

Muttukrishna, Shanthi; North, Robyn A.; Morris, JK; Schellenberg, Jean-Claude; Taylor, Rennae S.; Asselin, J; Ledger, William; Groome, Nigel P.; Redman, C. W. G.

doi:10.1093/humrep/15.7.1640

Cited by 194 publications

(87 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Activin A seems to be a sensitive marker for the risk of later development of preeclampsia at 21-25 wk of gestation [70] . Inhibin A is thought to be more sensitive than activin A in predicting cases of early-onset preeclampsia at 15-19 wk of gestation [70] . P-selectin P-selectin belongs to the group of cell adhesion molecules.…”

Section: Placental Protein 13mentioning

confidence: 99%

Preeclampsia from a renal point of view: Insides into disease models, biomarkers and therapy

Müller-Deile

Schiffer

2014

WJN

View full text Add to dashboard Cite

Proteinuria is a frequently detected symptom, found in 20% of pregnancies. A common reason for proteinuria in pregnancy is preeclampsia. To diagnose preeclampsia clinically and to get new insights into the pathophysiology of the disease it is at first essential to be familiar with conditions in normal pregnancy. Animal models and biomarkers can help to learn more about disease conditions and to find new treatment strategies. In this article we review the changes in kidney function during normal pregnancy and the differential diagnosis of proteinuria in pregnancy. We summarize different pathophysiological theories of preeclampsia with a special focus on the renal facets of the disease. We describe the current animal models and give a broad overview of different biomarkers that were reported to predict preeclampsia or have a prognostic value in preeclampsia cases. We end with a summary of treatment options for preeclampsia related symptoms including the use of plasmapheresis as a rescue therapy for so far refractory preeclampsia. Most of these novel biomarkers for preeclampsia are not yet implemented in clinical use. Therefore, we recommend using proteinuria (measured by UPC ratio) as a screening parameter for preeclampsia. Delivery is the only curative treatment for preeclampsia. In early preeclampsia the primary therapy goal is to prolong pregnancy until a state were the child has an acceptable chance of survival after delivery.© 2014 Baishideng Publishing Group Inc. All rights reserved.Key words: Preeclampsia; Pregnancy; Proteinuria; Biomarkers; Treatment Core tip: This review summarises different pathophysiological theories of preeclampsia with a special focus on the renal facets of the disease. In this context current animal models are presented. The reader gets a broad overview about different biomarkers for preeclampsia. Furthermore, the article discusses treatment options for preeclampsia related symptoms including the use of plasmapheresis as a rescue therapy for so far refractory preeclampsia.Müller-Deile J, Schiffer M. Preeclampsia from a renal point of view: Insides into disease models, biomarkers and therapy. World

show abstract

Section: Placental Protein 13mentioning

confidence: 99%

Preeclampsia from a renal point of view: Insides into disease models, biomarkers and therapy

Müller-Deile

Schiffer

2014

WJN

View full text Add to dashboard Cite

show abstract

“…In contrast, Silver et al [6] also examined women with PE, GH and normotensive controls and reported that the median value was 1.0 MoM in controls, 2.0 MoM in GH and 3.0 MoM in PE. Muttukrishna et al [43] measured serum activin A longitudinally during pregnancy and reported that during the third trimester the levels were significantly increased in both those developing PE and GH, but in the second trimester increased levels were observed only in the PE group. The possibility of different mechanisms underlying the increased serum activin A concentration in PE and GH was raised by a study investigating the effect of treating hypertension in such patients by ␣ -methyldopa [44] .…”

Section: Discussionmentioning

confidence: 99%

“…Muttukrishna et al [43] reported that at 21-25 weeks serum activin A was above the 90th and 95th percentiles in 59 and 38%, respectively, of cases that subsequently developed PE. Florio et al [16] estimated that screening for PE by activin A at 24 weeks would have a detection rate of 61% at a false positive rate of 11%.…”

Section: Discussionmentioning

confidence: 99%

Maternal Serum Activin A at 11–13 Weeks of Gestation in Hypertensive Disorders of Pregnancy

Akolekar¹,

Etchegaray²,

Zhou³

et al. 2009

Fetal Diagn Ther

View full text Add to dashboard Cite

Objectives: To investigate whether the maternal serum concentration of activin A at 11–13 weeks of gestation in pregnancies that subsequently develop hypertensive disorders is different from those with a normal outcome and to examine whether any possible differences are related to uterine artery pulsatility index (PI), serum pregnancy-associated plasma protein A (PAPP-A) and serum tumor necrosis factor-α receptor-1 (TNF-R1). Material and Methods: Serum activin A, TNF-R1, PAPP-A and uterine artery PI were determined in a case-control study of 126 cases that developed preeclampsia, 88 that developed gestational hypertension and 214 controls. Results: In preeclampsia, compared to controls, uterine artery PI, serum activin A and serum TNF-R1 were higher and serum PAPP-A was lower. In gestational hypertension, compared to controls, serum activin A was higher but uterine artery PI, serum PAPP-A and serum TNF-R1 were not significantly different. There were no significant associations between serum activin A and either uterine artery PI or serum TNF-R1 in either the hypertensive groups or the controls. Discussion: The data do not support the hypothesis linking activin A with impaired trophoblastic invasion of the maternal spiral arteries, placental hypoxia and the release of cytokines which in turn cause endothelial dysfunction and the development of the clinical symptoms of the disease.

show abstract

“…Muttukrishna et al found that maternal serum concentrations of inhibin A and activin A are more elevated in women with preeclampsia as compared to normotensive control women [23]. Some authors have confirmed that elevated inhibin A/activin A levels in first trimester [24,25] or in second trimester [26][27][28][29][30] could predict preeclampsia (Table II). Spence et al found that elevated inhibin A and activin A levels combined with uterine artery doppler measurement become a more accurate predictive values in second trimester [30].…”

Section: Inhibin a And Activin Amentioning

confidence: 96%

Prediction of the preeclampsia: a view of biochemical markers

Bostancı

Bayram

Cevrioğlu

et al. 2013

RHC

View full text Add to dashboard Cite

Preeclampsia is a diverse, multiorgan group of related disease processes that occurs in up to 5%-8% of pregnancies after 20 weeks' gestation and it is one of the leading causes of maternal and fetal morbidity and mortality. Many molecular mechanisms are contributed to the pathogenesis of preeclampsia. Although it is unknown whether the mechanisms act independently or have synergistic effects. This review describes review of primary papers investigating blood based biomarker such as PAP-A, Inhibin A, sFlt1, and PP13 in general and first trimester biochemical markers and combinations of them specifically for preeclampsia.

show abstract

Serum inhibin A and activin A are elevated prior to the onset of pre-eclampsia

Cited by 194 publications

References 31 publications

Preeclampsia from a renal point of view: Insides into disease models, biomarkers and therapy

Preeclampsia from a renal point of view: Insides into disease models, biomarkers and therapy

Maternal Serum Activin A at 11–13 Weeks of Gestation in Hypertensive Disorders of Pregnancy

Prediction of the preeclampsia: a view of biochemical markers

Contact Info

Product

Resources

About